Антифосфолипидный синдром - Насонов Е.Л.
ISBN 5-98216-010-5
Скачать (прямая ссылка):
71. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230—5.
72. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholes-terolemia. Circulation 2001; 103: 1191—3.
73. Ridker PM, Rifai N, Cleatfield M, et al. For the Air Force/Texas Coronary Athrerosclerosis Prevention of acute coronary evenrs. N Engl J Med 2001; 344: 1959—1965.
74. Albett MA, Danielson E, Rifai N, Ridker PM. for the PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64—70.
75. Jialal I, Stein D, Balis D. Effect of hydrox-ymethyl glutaryl coenzyme A reductase inhibitor
SHS-OOO4.qxd 21.11.2006 16:56 Page 432"
Насонов Е.Л. Антифосфолипидный синдром.
therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933—1935.
76. Weber C, Erl W, Weber PC. Lovastatin induces differentiation of Mono Mac 6 cells. Cell Biochem Funct 1995; 13: 273—277.
77. Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immuno-pharm 1996; 18: 669—675.
78. Wilson SH, Simari RD, Best PJ, et al. Simvastatin preserves coronary endothelial function in hypercholesterinemia in the absence of lipid lowering. Atheroscler Thromb Vasc Biol 2001; 21: 122—128.
79. Katoh M, Kurosawa Y, Tanaka K, et al. Fluvastatin inhibits O2- and ICAM-1 levels in a rat model with aortic remodeling induced by pressure overload. Am J Physiol Heart Circ Physiol 2001; 281: H655—660.
80. Tanaka K, Yasuhara M, Suzumura K, et al. Effects offuvastatin and its major metabolites on low-density lipoprotein oxidation and cholesterol esterification in macrophages. Jpn J Pharmacol 2001; 86: 289—296.
81. Shiomi M, Ito T. Effect of cerivastatin sodium, a new inhibotor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits. Br J Pharmacol 1999; 126: 961—968.
82. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitors, cerivas-tatin, suppress growth of macrophages expressing matrix metalloproteinase and tissue factor in vivo and in vitro. Circulation 2001; 103: 276— 283.
83. Bellosta S, Via D, Canaveis M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arteriol Thromb Vasc Biol 1998; 18: 1671—1678.
84. Buemi M, Allegra A, Senatore M, et al. Pro-apoptotic effect of fuvastatin on human smooth muscle cells. Eur JPharmacol 1999; 370:201—203.
85. Cutts JL, Bankhurst AD. Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lovastatin. Int J Immunopharmacol 1989; 11: 863—869.
86. Cipollone F, Mezzetti A, Porreca E, et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia. Effect of statin therapy. Circulation 2003; 106: 399—402. Circulation 2002; 106: 399—402.
87. Rezai-Majd A, Maca T, Bucek RA, et al. Simvastatin reduces expression of cytokines inter-leukin-6, interleukin-8, and monocyte chemoat-tractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arteriol Thromb Vasc Biol 2002; 22: 1194—1199.
88. Насонов ЕЛ. Перспективы применения статинов в ревматологии. РМЖ, 2003; 23: 1273—1276.
89. Насонов ЕЛ. Патогенетическое и клиническое обоснование применения статинов при системной красной волчанке и антифос-фолипидном синдроме. Клин. фарм. Терапия, 2004; 13: 1—8.
90. Roubey RAS. New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. Arthritis Rheum 2003; 48: 3004—3008.
91. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes to endothelium and reduce increased adhevsiveness of monocytes isolated from patients with hypercholesterinemia. J Am Col Cardiol 1997; 30: 1212—1227.
92. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7:687—692.
93. Frenette PS. Lockin a leukocyte integrin with stastin. New Engl J Med 2001; 345: 1419— 1421.
94. Meroni PL, Raschi E, Testoni C, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein 1) antibodies. Effect on the proadhesive and proun-flammatory phenotype. Arthritis Rheum 2001; 44: 2870—2878.
95. Ferrara D, Liu X, Espinola RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibody by fluvas-tatin in an in vivo model. Arthritis Rheum 2003; 48: 3272—3279.
